Compare Novo Nordisk A/S (NVO) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Sea Limited — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Sea Limited trades at $95.25 (market cap $56.89B). The key difference: Novo Nordisk A/S is far larger — about 2.9× Sea Limited's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Sea Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Sea Limited for 102 Days on average.
| NVO | SE | |
|---|---|---|
Market Cap | $165.31B | $56.89B |
Volume | 11,432,838 | 5,359,457 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $188.00 |
52-Week Low | $35.29 | $78.16 |
Typical Hold Time | 116 Days | 102 Days |
Enterprise Value | $179.56B | $51.92B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Sea Limited (SE) trades at $92.89, down 1.87% on the day, as technical indicators signal bearish momentum with the stock testing key support levels. Fundamentally, the company shows strong revenue growth with 2025 revenue reaching $22.94 billion and net income of $1.58 billion, though recent Q4 2025 earnings missed expectations. Analyst sentiment remains overwhelmingly positive with 31 buy ratings and a consensus price target of $153.67, representing significant upside potential from current levels.
The investment case hinges on Sea's continued e-commerce and fintech expansion, with Shopee's growth and Monee's profit potential driving long-term value. However, risks include competitive pressures, margin compression concerns, and recent insider selling activity. The current price decline presents a potential buying opportunity for investors believing in Sea's Southeast Asia growth story, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
